INTRODUCTION {#s1}
============

Whole-exome sequencing (WES) provides a comprehensive strategy to identify novel disease-associated genetic variants in patients with genetically heterogeneous conditions, including developmental abnormalities and intellectual disability (ID) ([@TanakaMCS000661C19]; [@TanakaMCS000661C22], [@TanakaMCS000661C23]; [@TanakaMCS000661C7]). Clinical WES is a powerful tool to identify de novo and inherited rare and novel variants ([@TanakaMCS000661C22], [@TanakaMCS000661C23]) for individuals in whom initial diagnostic genetic evaluation is unrevealing and/or in individuals without distinguishing clinical features suggestive of a diagnosis. Mutations in *CHAMP1* have recently been associated with global developmental delay, ID, hypotonia, and dysmorphic features ([@TanakaMCS000661C9]). Here we describe five unrelated individuals who have novel heterozygous variants in *CHAMP1* that are predicted to be deleterious. *CHAMP1* is located on Chromosome 13q34 and encodes a mammalian zinc finger protein involved in the proper alignment and segregation of chromosomes during mitosis ([@TanakaMCS000661C10]). We have identified five de novo novel predicted pathogenic variants in *CHAMP1* that are all associated with neurodevelopmental disorders and dysmorphic features and frequently associated with microcephaly.

RESULTS {#s2}
=======

Clinical Presentation {#s2a}
---------------------

Clinical WES was performed on 2144 individuals with developmental delay and/or intellectual disabilities, 148 of whom also had microcephaly. In three affected individuals from three unrelated families, we identified variants in *CHAMP1* as potentially causative for the phenotype. The fourth individual was identified at Greenwood Genetic Center and through GeneMatcher (<https://genematcher.org/>) (Sobreira et al. 2015). We identified another additional proband, for a total of five affected individuals in five families. All of the families were sequenced with WES performed as either a proband--parent trio or family analysis using affected or unaffected siblings in the segregation analysis. The father of one individual was a sperm donor, and we were unable to determine whether this particular variant is de novo.

Exome sequencing from three affected individuals' samples analyzed in the original clinical laboratory at GeneDx produced an average of ∼12 Gb of sequence per sample ([Table 1](#TanakaMCS000661TB1){ref-type="table"}). Mean coverage of the captured regions was ∼170× per sample, with \>98% covered with at least 10× coverage, an average of \>91% of base call quality of Q30 or greater, and an overall average mean quality score of \>Q35. Filtering of common SNPs (\>10% frequency present in 1000 Genomes \[1000G\] database) resulted in approximately 4500 variants per proband sample. We evaluated each of these variants by variant allele frequency in reference populations and filtered out variants with a minor allele frequency \>1%, known disease association, pattern of inheritance, and similarity of clinical phenotype among probands. Candidate disease causing variants in the *CHAMP1* gene were confirmed by Sanger sequencing. All five variants identified in the five families are rare and are highly conserved throughout across species. They include three nonsense and two frameshift deletion mutations. All five variants are predicted to be deleterious. No loss-of-function *CHAMP1* variants were detected in ExAC, 1000G, NHLBI Exome Sequencing Project (ESP), or our own internal database of 15,716 exomes.

###### 

Sequencing results

  Patient   10× cov (%)    Mean cov  Yield (Gb)    Q30   MeanQ   Filtered var   *CHAMP1* mean CDS cov   Var total fam cov   Samples   Mean per-sample var cov
  --------- ------------- ---------- ------------ ----- ------- -------------- ----------------------- ------------------- --------- -------------------------
  1         98.80            167     12.3          91     35         4597                302                  2053             3                684
  2         99.14            184     14.1          93     36         4652                313                  1157             3                386
  3         96.33            157     11.3          90     35         4310                239                   238             2                119
  Mean      98.82            169     12.6          91     36         4520                285                  1149             3                431

Results from individuals identified at GeneDx.

cov, coverage; CDS, coding sequence; var, variant; fam, family.

The five female individuals with *CHAMP1* pathogenic variants are all significantly intellectually disabled, three have congenital microcephaly, and one showed acquired microcephaly first noted at 6 mo of age (\<3%) ([Table 2](#TanakaMCS000661TB2){ref-type="table"}). They range in age from 4 to 23 yr old and are either nonverbal or minimally verbal, using signs and communication devices. Concerns were evident in the neonatal period with congenital microcephaly, hypotonia, and feeding difficulties. In addition, spasticity was a common feature, and one individual who was born prematurely and delivered at 34 wk had respiratory difficulties and apneic episodes. Some individuals, but not all, had congenital anomalies including choanal atresia, intestinal malrotation, bicuspid aortic valve, and a ventricular septal defect. All individuals exhibit short stature. However, weight ranges dramatically from underweight to overweight.

###### 

Clinical features of patients with mutations in *CHAMP1*

  Patient             Age     Sex   Mutation                            Inheritance   Muscle tone                                     Spasticity             Head circumference                     Current HT, WT                                            DD   Age at sitting    Age at walking   Verbal skills                         Vision                                           Hearing                         Brain MRI                                                        Seizure                       Abnormal Behavior
  ------------------- ------- ----- ----------------------------------- ------------- ----------------------------------------------- ---------------------- -------------------------------------- --------------------------------------------------------- ---- ----------------- ---------------- ------------------------------------- ------------------------------------------------ ------------------------------- ---------------------------------------------------------------- ----------------------------- --------------------------------------------------------------------------------
  1                   23 yo   F     c.1044delG p.Trp348\*               De novo       Hypotonia                                       Spastic quadriplegia   Congenital microcephaly (\<3 %ile)     HT = 152 cm (3rd %ile); WT = 72.4 kg (88th %ile)          Y    Unknown           18 mo            Nonverbal                             Normal                                           Moderate-severe BL SNHL         Hypoplastic corpus callosum                                      None                          Aggressive, occasionally self-injurious
  2                   7 yo    F     c.542_543delCT p.Ser181CysfsX5      De novo       Normal                                          Spastic quadriplegia   Relative microcephaly (10th %ile)      HT = 115.3 cm (10th %ile); WT = 28.5 kg (90th %ile)       Y    1 yo              2 yo             Put two words together at 5 yo        Strabismus, corrected                            Normal                          N/A                                                              Febrile seizures (resolved)   Skin-picking, rituals, food-foraging
  3                   4 yo    F     c.1945C\>T p.Gln649\*               De novo       Central hypotonia                               Spastic                Normal (75th %ile)                     HT = 107 cm (\<95th %ile); WT = 18.5 kg (\<90th %ile)     Y    6 mo              2 yo             Nonverbal                             Ocular albinism                                  Mild hearing loss in left ear   Normal                                                           None                          ADD/ADHD
  4                   12 yo   F     c.1969C\>T p.Gln657\*               De novo       Hypotonia                                       None                   Congenital microcephaly (\<3rd %ile)   HT = 124.46 cm (\<5th %ile); WT = 30 kg (\<5th %ile)      Y    18 mo             Nonambulatory    Has 2 words                           Strabismus                                       Normal                          Mildly decreased white matter, possible hypopituitarism          Seizures at 3 yo              Inappropriate laughter
  5                   6 yo    F     c.2029G\>T p.Glu677X                De novo       Severe truncal hypotonia in infancy, improved   None                   Acquired microcephaly (\<3rd %ile)     HT = 109.7 cm (\<25th %ile); WT = 19.1 kg (\<50th %ile)   Y    10 mo             2 yo             Nonverbal                             Alternating exotropia, accommodative esotropia   Mild hearing loss in one ear    Mild cerebellar atrophy with mild inferior vermian hypogenesis   None                          Hyperactivity
  Hempel et al. \#1   4 yo    M     c.1866_1867delCA p.Asp622Glufs\*8   De novo       Truncal and orofacial hypotonia                 N/A                    Congenital microcephaly (\<3rd %ile)   HT = 111.5 cm (97th %ile); WT = 16.3 kg (50th %ile)       Y    1 yo              4 yo             Has 3 words                           Strabismus, hyperopia                            Normal                          Mild brain atrophy and cerebellar cortical dysplasia             None                          Frequent hand fluttering, jactitation, very friendly
  Hempel et al. \#2   3 yo    M     c.1768C \> T p.Gln590\*             De novo       Severe hypotonia, improved                      N/A                    Microcephaly (\<3rd %ile)              HT = 86 cm (\<3rd %ile); WT = 14.7 kg (\<75th %ile)       Y    N/A               3 yo             Nonverbal                             Impaired                                         Normal                          Slightly delayed myelination                                     Frontotemporal epilepsy       Turning, twisting movements of arms and hands, sighing, shaking, friendly
  Hempel et al. \#3   18 yo   M     c.1192C \> T p.Arg398\*             De novo       Truncal and orofacial hypotonia                 N/A                    Microcephaly (\<3rd %ile)              HT = 160 cm (\<3rd %ile); WT = 50 kg (\<3rd %ile)         Y    1 yo              2 yo             Short sentences with slurred speech   Exotropia, hyperopia                             Normal                          Normal                                                           None                          Friendly
  Hempel et al. \#4   3 yo    F     c.635delC p.Pro212Leufs\*7          De novo       Mild truncal hypotonia                          N/A                    Congenital microcephaly (\<3rd %ile)   HT = 93.5 cm (\<50th %ile); WT = 14.7 kg (75th %ile)      Y    N/A               1 yo             Impaired speech development           Hyperopia, astigmatism                           Normal                          Normal                                                           None                          Friendly, hand stereotypies, tactile hypersensitivity, sexual self-stimulation
  Hempel et al. \#5   9 yo    F     c.1192C \> T p.Arg398\*             De novo       Truncal and orofacial hypotonia                 N/A                    Normal (\<75th %ile)                   HT = 139 cm (\>95th %ile); WT = 52 kg (\>95th %ile)       Y    N/A               1 yo             Three word sentences                  Hyperopia, astigmatism                           Normal                          Normal                                                           None                          Friendly

See Supplemental Table 1 for additional details of clinical presentations.

DD, developmental delay; yo, years old; BL, bilateral; SNHL, sensorineural hearing loss; ADD, attention deficit disorder; ADHD, attention deficit hyperactivity disorder; N/A, not available; mo, months.

Brain structure by MRI in two patients suggested no specific structural abnormalities, but there was decreased brain volume and white matter in one individual, hypoplastic corpus callosum in another, and cerebellar atrophy with mild inferior vermian hypogenesis in a third ([Table 2](#TanakaMCS000661TB2){ref-type="table"}). Seizures were observed in two individuals: febrile seizures that resolved in one and generalized seizures that started at age 3 and were adequately treated with levetiracetam in another. There were a range of abnormal behaviors including self-injurious behavior in the oldest individual, repetitive behaviors, and inappropriate laughter. Four individuals had difficulty with sleeping and remaining asleep. Two individuals had strabismus, one individual had foveal hypoplasia, blond fundus, and nystagmus, and a fourth had alternating exotropia and accommodative esotropia. One individual had bilateral sensorineural hearing loss and two others have decreased hearing unilaterally. Dysmorphic features were common to all the individuals and included hypertelorism, epicanthal folds, short philtrum, and upslanting or downslanting palpebral fissures ([Fig. 1](#TanakaMCS000661F1){ref-type="fig"}).

![Photographs of patients. (*A*,*B*) Patient 1. (*C*,*D*) Patient 3. (*E*,*F*) Patient 4. (*G*) Patient 5 at 1 yr of age. (*H*,*I*) Patient 5 at 6 yr. Note midface hypoplasia, upslanted palpebral fissures (*A*), and clinodactyly (*B*) in Patient 1, hypertelorism in Patients 1 and 3, short philtrum and pointed chin in Patient 5, and widely spaced teeth in Patients 1, 3, and 4, and broad nasal bridge in all four patients.](TanakaMCS000661_F1){#TanakaMCS000661F1}

DISCUSSION {#s3}
==========

Five individuals with a shared phenotype of global developmental delay, significant ID, and dysmorphic features were all found to have predicted loss-of-function novel variants in *CHAMP1* identified by WES, all of which have been confirmed as de novo. A recent report of five patients with similar clinical features of ID, hypotonia, severe speech impairment, and dysmorphisms identified de novo mutations in *CHAMP1*, including two frameshift and two nonsense mutations ([@TanakaMCS000661C9]). One of the nonsense mutations, c.1192C\>T (p.Arg398\*), was found in two affected individuals ([@TanakaMCS000661C9]). *CHAMP1* encodes a zinc finger protein that plays a key role in chromosome alignment during metaphase in mitosis and has been identified as a candidate gene involved in ID ([@TanakaMCS000661C7]). One study identified the identical c.1192C\>T (p.Arg398\*) de novo nonsense variant in *CHAMP1* in two individuals with severe nonsyndromic ID by WES ([@TanakaMCS000661C17]). Another large-scale WES study implicated 12 novel genes enriched for damaging de novo variants with evidence for a role in developmental disorders. WES of 1133 children with severe, undiagnosed developmental disorders and their parents identified *CHAMP1* loss-of-function variants in two individuals ([@TanakaMCS000661C5]). Two heterozygous loss-of-function frameshift deletion variants, c.1450delT (p.Phe485fs\*100) and c.1596delC (p.Glu533fs\*52) have also been reported from colon cancer samples in the Catalog of Somatic Mutations in Cancer (COSMIC; <http://cancer.sanger.ac.uk/cosmic>). Our additional five patients expand the number of individuals and the associated phenotypes of de novo *CHAMP1* loss-of-function alleles.

CHAMP1 is an 812-amino acid protein first identified in human embryonic kidney 293 (HEK293) cells in a cellular screen for mitotic arrest deficient-like 2 (MAD2L2) protein interactors. The protein encoded by *MAD2L2* is a component of the mitotic spindle assembly checkpoint complex, which regulates the onset of anaphase by monitoring the proper alignment of chromosomes at the metaphase plate during mitosis. MAD2L2 also regulates DNA repair activity in multiple settings by promoting nonhomologous end joining (NHEJ) at telomeres and double-strand breaks ([@TanakaMCS000661C3]). CHAMP1 binds to MAD2L2 and is required for localization of MAD2L2 to the mitotic spindle. Depletion of *CHAMP1* results in misaligned chromosomes and abnormal chromosome segregation potentially resulting in mitotic arrest or mitotic errors such as aneuploidy ([@TanakaMCS000661C10]).

Previous reports of deletions in the 13q33-34 region including 11 common genes have been associated with ID, microcephaly, distinct dysmorphic facial features, and congenital heart disease ([@TanakaMCS000661C20]; [@TanakaMCS000661C14]). *CHAMP1* is located at 13q34 and is expressed during fetal brain development ([@TanakaMCS000661C15]) and throughout all fetal and adult tissues, including specific brain regions ([@TanakaMCS000661C8]). *CHAMP1* encodes a highly evolutionarily conserved zinc finger protein in mammals with no homolog in worms, flies, or yeast ([@TanakaMCS000661C10]). The protein consists of five C2H2 zinc-finger domains and several characteristic repeat motifs, including the SPE (consensus: PxxSPExxK), WK (SPxxWKxxP), and FPE (FPExxK) motifs ([Fig. 2](#TanakaMCS000661F2){ref-type="fig"}). [@TanakaMCS000661C10] demonstrated the FPE region facilitates kinetochore--microtubule attachment and is necessary for proper chromosome alignment. Proteins involved in the proper alignment of the mitotic spindle are important in maintaining symmetric and asymmetric cell divisions and for controlling cell proliferation. Spindle orientation defects and aberrant functioning centromere proteins, such as Centromere Protein F (CENPF), have been associated with neurological and brain diseases including lissencephaly and primary microcephaly (MCPH) ([@TanakaMCS000661C1]; [@TanakaMCS000661C16]; [@TanakaMCS000661C21]) and could account for the microcephaly observed in individuals with *CHAMP1* variants. Twelve genes, *MCPH1--MCPH12*, are implicated in MCPH, of which nine are directly involved in regulating mitosis or cell cycle progression ([@TanakaMCS000661C2]). Accurate chromosome segregation is required for progression of mitosis and normal development. Missegregation is associated with aneuploidy and premature chromatid separation (PCS) (MIM \#176430) caused by defects in the mitotic checkpoint protein BUB1 mitotic checkpoint serine/threonine kinase B (BUB1B). Multiple congenital abnormalities, dysmorphism, and mosaic variegated aneuploidy (MIM \#257300), a rare cytogenetic disorder characterized by mosaicism for several different aneuploidies involving many different chromosomes, arise from dysregulation of mitotic checkpoint proteins, including BUB1B, and defects in kinetochore--microtubule complex proteins ([@TanakaMCS000661C1]). Individuals with PCS and mosaic-variegated aneuploidies have severe ID, microcephaly, and growth retardation. We hypothesize that abnormal or decreased binding of CHAMP1 to its targets in coordinating kinetochore--microtubule attachment may be responsible for altered brain development and function and the dysmorphisms seen in individuals with mutations in *CHAMP1*. Additional studies of *CHAMP1* are necessary to elucidate the molecular mechanism of *CHAMP1-*associated encephalopathy and growth retardation, but we hypothesize that the variants we describe result in haploinsufficiency of CHAMP1 and expand the genes involved in mitosis and cell cycle progression that can result in microcephaly and intellectual disabilities when mutated.

![Variants in CHAMP1. Diagram of CHAMP1 with C2H2-type zinc finger domains (blue), SPE motifs (yellow), WK motifs (pink), and FPE motifs (green). Gene disrupting nonsense and frameshift variants identified in our patients are in green and previously identified mutations are shown in orange ([@TanakaMCS000661C17]; [@TanakaMCS000661C9]).](TanakaMCS000661_F2){#TanakaMCS000661F2}

METHODS {#s4}
=======

Whole-Exome Sequencing {#s4a}
----------------------

Genomic DNA was extracted from whole blood from the affected children and their parents. For three of the individuals, exome sequencing was performed at GeneDx on exon targets isolated by capture using the Agilent SureSelect Human All Exon V4 (50 Mb) kit (Agilent Technologies). One microgram of DNA from blood specimen was sheared into 350--400-bp fragments, which were then repaired, ligated to adaptors, and purified for subsequent PCR amplification. Amplified products were then captured by biotinylated RNA library baits in solution following the manufacturer\'s instructions. Bound DNA was isolated with streptavidin-coated beads and reamplified. The final isolated products were sequenced using the Illumina HiSeq 2000 or 2500 sequencing system with 100-bp paired-end reads (Illumina). DNA sequence was mapped to the published human genome build UCSC hg19/GRCh37 reference sequence using BWA with the latest internally validated version at the time of sequencing, progressing from BWA v0.5.8 through BWA-MEM v0.7.8 ([@TanakaMCS000661C12]; [@TanakaMCS000661C11]). Targeted coding exons and splice junctions of known protein-coding RefSeq genes were assessed for average depth of coverage with a minimum depth of 10× required for inclusion in downstream analysis. Local realignment around insertion--deletion sites was performed using the Genome Analysis Toolkit v1.6 ([@TanakaMCS000661C6]). Variant calls were generated simultaneously on all sequenced family members using SAMtools v0.1.18 ([@TanakaMCS000661C13]). All coding exons and surrounding intron/exon boundaries were analyzed. Automated filtering removed common sequence changes (defined as \>10% frequency present in 1000 Genomes database). The targeted coding exons and splice junctions of the known protein-coding RefSeq genes were assessed for the average depth of coverage and data quality threshold values. WES data for all sequenced family members was analyzed using GeneDx\'s XomeAnalyzer (a variant annotation, filtering, and viewing interface for WES data), which includes nucleotide and amino acid annotations, population frequencies (NHLBI Exome Variant Server and 1000 Genomes databases), in silico prediction tools, amino acid conservation scores, and mutation references. Variants were filtered based on inheritance patterns, gene lists of interest, phenotype, and population frequencies, as appropriate. Resources including the Human Gene Mutation Database (HGMD), 1000 Genomes database, NHLBI Exome Variant Server, OMIM, PubMed, and ClinVar were used to evaluate genes and detected sequence changes of interest. The general assertion criteria for variant classification are publicly available on the GeneDx ClinVar submission page (<http://www.ncbi.nlm.nih.gov/clinvar/submitters/26957/>). Additional searches were performed using specific gene lists related to the patients' clinical features. Identified sequence changes of interest were confirmed in all members of the trio by conventional di-deoxy DNA sequence analysis using an ABI3730 (Life Technologies) and standard protocols with a new DNA preparation.
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